SCHEMBL3577414

SCHEMBL3577414

CC(C)(C)OC(=O)N[C@@H](CNc1ncnc(Cl)c1N)C(=O)OC1CCCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 6/20 0.47
AAK1 Q2M2I8 2/20 0.35
BTK Q06187 2/20 0.34
P2RY2 P41231 1/20 0.34
CTSS P25774 1/20 0.34
CTSK P43235 1/20 0.34
NPR3 P17342 1/20 0.34
KLK7 P49862 2/20 0.33
KLK5 Q9Y337 2/20 0.33
WDR5 P61964 1/20 0.33
KMT2A Q03164 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
PKM P14618 1/20 0.33
HPGD P15428 1/20 0.33
ALOX12 P18054 1/20 0.33
EGFR P00533 1/20 0.33
SYK P43405 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20050106 0.86 SYK (0.39) AAK1P2RY2CTSKKLK5WDR5
SCHEMBL15956011 0.83 PPARA (0.41) P2RY2EGFRSYK
SCHEMBL3580317 0.83 PPARA (0.41) P2RY2EGFRSYK
SCHEMBL3579148 0.75 CACNA1B (0.45) CACNA1BHDAC6
SCHEMBL20050109 0.71 EGFR (0.32) EGFRSYK
SCHEMBL31398897 0.71 PPARA (0.41) P2RY2CTSSEGFRSYK
SCHEMBL375820 0.71 CACNA1B (0.56) CACNA1BCTSSCTSKKLK5KMT2A
SCHEMBL3578046 0.71 ALDH1A1 (0.44) CACNA1BALDH1A1
SCHEMBL375994 0.71 CACNA1B (0.49) CACNA1BAAK1CTSSCTSKKLK7
SCHEMBL14196749 0.71 CACNA1B (0.49) CACNA1BCTSSCTSKKLK7HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8217050-B2 Adenine derivative as inhibitors of HSP90 for the treatment of cancer CHROMA THERAPEUTICS LIMITED (GB) 2012-07-10 US disclosed
US-20100035901-A1 ADENINE DERIVATIVE AS INHIBITORS OF HSP90 FOR THE TREATMENT OF CANCER CHROMA THERAPEUTICS LTD. 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035901-A1 ADENINE DERIVATIVE AS INHIBITORS OF HSP90 FOR THE TREATMENT OF CANCER HSP90AA1, HSP90AB1, HSP90B1 CACNA1B 4810/4885AAK1 721/4885BTK 2784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.